How well does Orserdu(Elacestrant) work?

ORSERDU (elacestrant) is an oral estrogen receptor antagonist indicated for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in postmenopausal women or adult men following disease progression after prior endocrine therapy, demonstrating improved progression-free survival in clinical trials.

Therapeutic Efficacy and Clinical Application of Elacestrant in ESR1-Mutated Advanced Breast Cancer

ORSERDU (elacestrant) exerts its therapeutic effect by antagonizing estrogen receptor-alpha (ERα), inducing receptor degradation via the proteasomal pathway, thereby inhibiting estrogen-driven tumor proliferation. It is specifically effective in ER-positive, HER2-negative breast cancer harboring activating ESR1 mutations, a subgroup resistant to prior endocrine therapies, including CDK4/6 inhibitors. In the EMERALD trial, patients with ESR1 mutations treated with ORSERDU achieved a median progression-free survival (PFS) of 3.8 months versus 1.9 months in the control group (fulvestrant/aromatase inhibitors), with a hazard ratio of 0.55 (95% CI: 0.39–0.77).

Related Columns

Elacestrant(Orserdu)

Advanced or metastatic breast cancer that is ER-positive, HER2-negative, and...

WeChat Scan
Free Inquiry

What is the therapeutic effect of Elacestrant?

Elacestrant was developed and produced by Stemline, the United States, and was approved by the U.S. Food and Drug Administration (FDA) in January 2023, becoming the only oral selective estrogen recept...

How effective is Elacestrant?

In the treatment of breast diseases, the emergence of Elacestrant is of great significance. As an oral SERD, it is able to directly degrade estrogen receptors, thereby inhibiting the growth of disease...

Is Elacestrant(ORSERDU) effective?

The launch of the breast disease treatment drug ORSERDU/Elacestrant has brought new vitality to countless patients. This drug selectively degrades estrogen receptors and effectively blocks the growth ...